Stem Cell Adjunct to LVAD Trial Negative, But ‘Intriguing’

November 19, 2018

(Medscape) – The largest trial to date investigating the use of stem cells to enhance myocardial recovery in patients who have received a left ventricular assist device (LVAD) missed the primary end point of improved cardiac function, but has shown some intriguing results. The study, which investigated the injection of allogeneic mesenchymal progenitor cells into the myocardium of patients receiving an LVAD device, did appear to show an improvement in patients with ischemic heart failure.